Activities of telithromycin against 13,874 Streptococcus pneumoniae isolates collected between 1999 and 2003

被引：41

作者：

Farrell, DJ ^{[1
]}

Felmingham, D ^{[1
]}

机构：

[1] GR Micro Ltd, Med & Mol Microbiol, London NW1 3ER, England

来源：

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 2004年 / 48卷 / 05期

关键词：

D O I：

10.1128/AAC.48.5.1882-1884.2004

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

Telithromycin MICs for 13,874 Streptococcus pneumoniae isolates collected in the first 3 years of the global PROTEKT study (1999 to 2003) were studied. There was no change in the distribution of telithromycin MICs over this period, even in countries where telithromycin is in use. The telithromycin MICs for 10 isolates (0.07%) were greater than or equal to4 mug/ml, and these 10 isolates contained erm(B); there was no evidence of reproducible clonal spread between centers.

引用

页码：1882 / 1884

页数：3

共 8 条

[1] Activity of telithromycin and seven other agents against 1034 pediatric Streptococcus pneumoniae isolates from ten central and eastern European centers [J].

Bozdogan, B ;

Appelbaum, PC ;

Kelly, LM ;

Hoellman, DB ;

Tambic-Andrasevic, A ;

Drukalska, L ;

Hryniewicz, W ;

Hupkova, H ;

Jacobs, MR ;

Kolman, J ;

Konkoly-Thege, M ;

Miciuleviciene, J ;

Pana, M ;

Setchanova, L ;

Trupl, J ;

Urbaskova, P .

CLINICAL MICROBIOLOGY AND INFECTION, 2003, 9 (07) :653-661

[2] Antipneumococcal activity of telithromycin by agar dilution, microdilution, E test, and disk diffusion methodologies [J].

Davies, TA ;

Kelly, LM ;

Jacobs, MR ;

Appelbaum, PC .

JOURNAL OF CLINICAL MICROBIOLOGY, 2000, 38 (04) :1444-1448

[3] Macrolide resistance by ribosomal mutation in clinical isolates of Streptococcus pneumoniae from the PROTEKT 1999-2000 study [J].

Farrell, DJ ;

Douthwaite, S ;

Morrissey, I ;

Bakker, S ;

Poehlsgaard, J ;

Jakobsen, L ;

Felmingham, D .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2003, 47 (06) :1777-1783

[4] Molecular characterization of macrolide resistance mechanisms among Streptococcus pneumoniae and Streptococcus pyogenes isolated from the PROTEKT 1999-2000 study [J].

Farrell, DJ ;

Morrissey, I ;

Bakker, S ;

Felmingham, D .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2002, 50 :39-47

[5] The need for antimicrobial resistance surveillance [J].

Felmingham, D .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2002, 50 :1-7

[6] Increasing prevalence of antimicrobial resistance among isolates of Streptococcus pneumoniae from the PROTEKT surveillance study, and compatative in vitro activity of the ketolide, telithromycin [J].

Felmingham, D ;

Reinert, RR ;

Hirakata, Y ;

Rodloff, A .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2002, 50 :25-37

[7] Community-acquired respiratory tract infections caused by resistant pneumococci: clinical and bacteriological efficacy of the ketolide telithromycin [J].

Fogarty, CM ;

Kohno, S ;

Buchanan, P ;

Aubier, M ;

Baz, M .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2003, 51 (04) :947-955

[8] Telithromycin- and fluoroquinolone-resistant Streptococcus pneumoniae in Taiwan with high prevalence of resistance to macrolides and β-lactams:: SMART program 2001 data [J].

Hsueh, PR ;

Teng, LJ ;

Wu, TL ;

Yang, D ;

Huang, WK ;

Shyr, JM ;

Chuang, YC ;

Wan, JH ;

Yan, JJ ;

Lu, JJ ;

Wu, JJ ;

Ko, WC ;

Chang, FY ;

Yan, YC ;

Lau, YJ ;

Liu, YC ;

Lee, CM ;

Leu, HS ;

Liu, CY ;

Luh, KT .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2003, 47 (07) :2145-2151

← 1 →